Literature DB >> 28820925

Oxidative Stress-Related Molecular Biomarker Candidates for Glaucoma.

Gözde Hondur1, Emre Göktas1, Xiangjun Yang1, Lama Al-Aswad1, James D Auran1, Dana M Blumberg1, George A Cioffi1, Jeffrey M Liebmann1, Leejee H Suh1, Danielle Trief1, Gülgün Tezel1.   

Abstract

Purpose: Glaucoma-related molecular biomarkers can improve clinical testing to diagnose the disease early, predict its prognosis, and monitor treatment responses. Based on the evidence of increased oxidative stress in glaucomatous tissues, this study analyzed oxidative stress-related biomarker candidates in blood and aqueous humor samples with or without glaucoma.
Methods: The blood and aqueous humor samples collected from carefully selected groups of 96 patients with glaucoma and 64 healthy subjects without glaucoma were included in the study. The samples were analyzed for protein carbonyls and advanced glycation end products (AGEs) through ELISA-based quantification assays. To allow proper comparisons, the Goldmann-Witmer coefficient that reflects the ratio of aqueous humor to blood values corrected to total protein concentration in individual samples was calculated.
Results: Blood and aqueous humor levels of protein carbonyls and AGEs were found significantly higher in glaucomatous samples compared with age-matched nonglaucomatous controls (P < 0.001). The glaucoma-related increase in protein carbonyls and AGEs was more prominent in aqueous humor samples than blood samples (2.6-fold versus 1.9-fold for protein carbonyls, and 3.1-fold versus 1.9-fold for AGEs; P < 0.001). Comparison of the Goldmann-Witmer coefficients indicated greater values for protein carbonyls (1.37 ± 0.3 vs. 3.07 ± 0.8) and AGEs (1.2 ± 0.3 vs. 3.2 ± 1.1) in the glaucoma group (P < 0.001). Conclusions: Findings of this study encourage further validation studies of oxidative stress-related biomarkers in glaucoma. Analysis of protein carbonyls and AGEs in longitudinal studies of larger and heterogeneous patient cohorts should better assess the value of these promising candidates as molecular biomarkers of glaucoma for clinical predictions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28820925      PMCID: PMC5685420          DOI: 10.1167/iovs.17-22242

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  59 in total

1.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Protein oxidation in aging, disease, and oxidative stress.

Authors:  B S Berlett; E R Stadtman
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.

Authors:  C D Smith; J M Carney; P E Starke-Reed; C N Oliver; E R Stadtman; R A Floyd; W R Markesbery
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 4.  Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.

Authors:  C Gustavo De Moraes; Jeffrey M Liebmann; Leonard A Levin
Journal:  Prog Retin Eye Res       Date:  2016-10-20       Impact factor: 21.198

5.  Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma.

Authors:  Gülgün Tezel; Xiangjun Yang; Jian Cai
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-09       Impact factor: 4.799

6.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.

Authors:  Alessandra Castegna; Michael Aksenov; Marina Aksenova; Visith Thongboonkerd; Jon B Klein; William M Pierce; Rosemarie Booze; William R Markesbery; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2002-08-15       Impact factor: 7.376

7.  ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture.

Authors:  Neville N Osborne; Dan Ji; Aman S Abdul Majid; Rebecca J Fawcett; Anna Sparatore; Piero Del Soldato
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-26       Impact factor: 4.799

Review 8.  The dysfunction of the trabecular meshwork during glaucoma course.

Authors:  Sergio Claudio Saccà; Alessandra Pulliero; Alberto Izzotti
Journal:  J Cell Physiol       Date:  2015-03       Impact factor: 6.384

9.  Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects.

Authors:  Zilin Sun; Jiajia He; Shanhu Qiu; Chenghao Lei; Yi Zhou; Zuolin Xie; Lin Zhang; Yanping Wang; Hui Jin
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Advanced Glycation End Products Evolution after Pancreas-Kidney Transplantation: Plasmatic and Cutaneous Assessments.

Authors:  La Salete Martins; José C Oliveira; José Ramón Vizcaíno; Isabel Fonseca; Carlos Gouveia; Donzília Silva; António C Henriques; Irene L Noronha; Anabela Rodrigues
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

View more
  16 in total

1.  Association of Long-term Ambient Black Carbon Exposure and Oxidative Stress Allelic Variants With Intraocular Pressure in Older Men.

Authors:  Jamaji C Nwanaji-Enwerem; Weiye Wang; Onyemaechi Nwanaji-Enwerem; Pantel Vokonas; Andrea Baccarelli; Marc Weisskopf; Leon W Herndon; Janey L Wiggs; Sung Kyun Park; Joel Schwartz
Journal:  JAMA Ophthalmol       Date:  2019-02-01       Impact factor: 7.389

2.  Associations between the red blood cell distribution width and primary angle-closure glaucoma: a potential for disease prediction.

Authors:  Qiang Chen; Bin Zhao; Meng-Ya Wang; Xue-Yu Chen; Dong Li; Xin-Quan Jiang; Jing-Hui Tian; Yong-Jun Liu
Journal:  EPMA J       Date:  2019-04-05       Impact factor: 6.543

Review 3.  Multiplex protein analysis for the study of glaucoma.

Authors:  Gülgün Tezel
Journal:  Expert Rev Proteomics       Date:  2021-10-29       Impact factor: 3.940

Review 4.  Association Between Diabetes, Diabetic Retinopathy, and Glaucoma.

Authors:  Yangjiani Li; William Mitchell; Tobias Elze; Nazlee Zebardast
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 5.430

Review 5.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

6.  Effect of Myricetin on Primary Open-angle Glaucoma.

Authors:  Qing Yang; Ying Li; Lin Luo
Journal:  Transl Neurosci       Date:  2018-11-12       Impact factor: 1.757

7.  Association between Pretreatment Serum Uric Acid Levels and Progression of Newly Diagnosed Primary Angle-Closure Glaucoma: A Prospective Cohort Study.

Authors:  Shengjie Li; Mingxi Shao; Wenjun Cao; Xinghuai Sun
Journal:  Oxid Med Cell Longev       Date:  2019-02-07       Impact factor: 6.543

8.  T-Lymphocyte Subset Distribution and Activity in Patients With Glaucoma.

Authors:  Xiangjun Yang; Qun Zeng; Emre Göktas; Kalashree Gopal; Lama Al-Aswad; Dana M Blumberg; George A Cioffi; Jeffrey M Liebmann; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-03-01       Impact factor: 4.799

9.  The mito-QC Reporter for Quantitative Mitophagy Assessment in Primary Retinal Ganglion Cells and Experimental Glaucoma Models.

Authors:  Ines Rosignol; Beatriz Villarejo-Zori; Petra Teresak; Elena Sierra-Filardi; Xandra Pereiro; Natalia Rodríguez-Muela; Elena Vecino; Helena L A Vieira; Katharina Bell; Patricia Boya
Journal:  Int J Mol Sci       Date:  2020-03-10       Impact factor: 5.923

Review 10.  The Role of MicroRNAs in Mitochondria-Mediated Eye Diseases.

Authors:  Sabrina Carrella; Filomena Massa; Alessia Indrieri
Journal:  Front Cell Dev Biol       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.